Medicare AdvantageCoverageMedium impact
MA06.021d, In Vitro Chemosensitivity and Chemoresistance Assays
Independence Blue Cross·Oncology, Hematology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.021d covering In Vitro Chemosensitivity and Chemoresistance Assays has been reissued effective October 1, 2025. This policy update affects coverage and billing requirements for specialized cancer treatment testing procedures used to determine optimal chemotherapy drugs for patients.
Action Required
By October 1, 2025: Billing team must review updated policy MA06.021d for In Vitro Chemosensitivity and Chemoresistance Assays to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage plans. Access full policy details at the provided URL to identify specific billing code changes and documentation requirements.